Metabolism - Clinical and Experimental
Volume 44, Issue 6 , Pages 712-718 , June 1995

Factors affecting lipoprotein lipase in hypertensive patients

  • Teodoro Marotta

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Teodoro Marotta, MD, PhD, Istituto di Medicina Interna e Malattie Dismetaboliche, Facoltà di Medicina e Chirurgia, Università degli Studi di Napoli “Federico II,” Via Sergio Pansini 5, 80131 Napoli, Italia.
    • Institute of Internal Medicine and Metabolic Diseases, Federico II University, Naples, Italy
    • Institute of Pharmacology and Toxicology, 2nd University of Naples, Naples, Italy
    • ,
  • Liberato Aldo Ferrara

      Affiliations

    • Institute of Internal Medicine and Metabolic Diseases, Federico II University, Naples, Italy
    • Institute of Pharmacology and Toxicology, 2nd University of Naples, Naples, Italy
    • ,
  • Lucrezia Di Marino

      Affiliations

    • Institute of Internal Medicine and Metabolic Diseases, Federico II University, Naples, Italy
    • Institute of Pharmacology and Toxicology, 2nd University of Naples, Naples, Italy
    • ,
  • Marcello Mancini

      Affiliations

    • Institute of Internal Medicine and Metabolic Diseases, Federico II University, Naples, Italy
    • Institute of Pharmacology and Toxicology, 2nd University of Naples, Naples, Italy
    • ,
  • Giovanni Annuzzi

      Affiliations

    • Institute of Internal Medicine and Metabolic Diseases, Federico II University, Naples, Italy
    • Institute of Pharmacology and Toxicology, 2nd University of Naples, Naples, Italy
    • ,
  • Ornella Russo

      Affiliations

    • Institute of Internal Medicine and Metabolic Diseases, Federico II University, Naples, Italy
    • Institute of Pharmacology and Toxicology, 2nd University of Naples, Naples, Italy
    • ,
  • Gennaro D'Orta

      Affiliations

    • Institute of Internal Medicine and Metabolic Diseases, Federico II University, Naples, Italy
    • Institute of Pharmacology and Toxicology, 2nd University of Naples, Naples, Italy
    • ,
  • Carmela Lucarelli

      Affiliations

    • Institute of Internal Medicine and Metabolic Diseases, Federico II University, Naples, Italy
    • Institute of Pharmacology and Toxicology, 2nd University of Naples, Naples, Italy
    • ,
  • Francesco Rossi

      Affiliations

    • Institute of Internal Medicine and Metabolic Diseases, Federico II University, Naples, Italy
    • Institute of Pharmacology and Toxicology, 2nd University of Naples, Naples, Italy

Received 21 July 1993 ,Accepted 28 October 1994.

References 

  1. Reader R, Bauer GE, Doyle AE, et al.  The Australian Therapeutic Trial in Mild Hypertension. Lancet. 1980;1:1261–1270
  2. Assmann G. The Prospective Cardiovascular Münster (PROCAM) Study: Prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J. 1988;116:1713–1724
  3. Stamler J, Westworth D, Neaton JD, et al.  Factor Intervention Trial Research Group: Is the relation between serum cholesterol and risk of premature death from coronary heart disease continuous and graded?. In: Findings in 356222 primary screenes of the Multiple Risk Factor Intervention Trial (MRFIT). ed 2. JAMA. 256:1986;p. 2823–2828
  4. Laurenzi M, Mancini M, Menotti A, et al.  Multiple risk factors in hypertension: Results from the Gubbio study. J Hypertens. 1990;8:S7–S12 suppl 1
  5. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607
  6. Ferrannini E. Metabolic abnormalities of hypertension. In: A lesson in complexity. ed 2. Hypertension. 18:1991;p. 636–639
  7. In:  Borensztajn J editors. Lipoprotein Lipase. Chicago, IL: Evener; 1987;
  8. Foster DW. Insulin resistance—A secret killer?. N Engl J Med. 1989;320:733–734
  9. Slater EE. Insulin resistance and hypertension. Hypertension. 1991;18:I108–I114 (suppl)
  10. Pollare T, Vessby B, Lithell H. Lipoprotein lipase activity in skeletal muscle is related to insulin sensitivity. Arterioscler Thromb. 1991;11:1192–1203
  11. Sacks FM, Dzau VJ. Adrenergic effects on plasma lipoprotein metabolism: Speculation on mechanism of action. Am J Med. 1986;80:71–81 suppl 2A
  12. Weidmann P, Uehlinger DE, Gerber A. Antihypertensive treatment and serum lipoproteins. J Hypertens. 1985;3:297–306
  13. Thaulow E, Nitter-Hauge S. Antihypertensive therapy and blood lipids: Alpha blockers. Scand J Clin Lab Invest. 1990;50:45–48 Suppl 99
  14. Rössner S. Studies on an intravenous fat tolerance test. In: Methodological, experimental and clinical experience with Intralipid. ed 2. Acta Med Scand. 1974;p. 1–24 [Suppl 564]
  15. Hyelm M. Enzymatic determination of hexoses in blood and urine. Scand J Invest. 1966;18:85–98 Suppl 192
  16. Siedel J, Schlumberger H, Klose S, et al.  Improved reagent for enzymatic determination of serum cholesterol. J Clin Chem Clin Biochem. 1981;19:838–839
  17. Wahlefeld AW. Triglycerides determination after enzymatic hydrolysis. In: ed 2.  Bergemeyer HU editors. Methods of Enzymatic Analysis. vol 4:New York, NY: Academic; 1974;p. 1831–1974
  18. Kostner GM. Enzymatic determination of cholesterol in high density lipoprotein fractions prepared by polyanion precipitation. Clin Chem. 1976;22:695–698
  19. De Lalla O, Gofman JW. Ultracentrifugal analysis for plasma lipoproteins. In: ed 2.  Glick P editors. Methods of Biochemical Analysis. vol 1:New York, NY: Interscience; 1954;p. 459–478
  20. Marcovina S, Di Cola G, Rapetto G, et al.  Development of a radial immunodiffusion technique employing monoclonal antibodies for apoprotein B determination in human plasma. Clin Chim Acta. 1985;147:117–125
  21. Marcovina S, Di Cola G, Catapano AL. Radial immunodiffusion assay of human apoprotein A1 with use of two monoclonal antibodies combined. Clin Chem. 1986;32:2155–2159
  22. Debuquois B, Aurbach GD. Use of polyethylene glycol to separate free and antibody bound peptide hormones in radioimmunoassay. J Clin Endocrinol Metab. 1971;33:732–738
  23. Nilsson-Ehle P. Measurements of lipoprotein lipase activity. In:  Borensztajn J editors. Lipoprotein Lipase. Chicago, IL: Evener; 1987;p. 59–77
  24. Foti A, Kimura S, De Quattro V, et al.  Liquid-chromatographic measurement of catecholamines in plasma and urine. Clin Chem. 1987;33:2209–2213
  25. Coats AJS. Doppler ultrasonic measurement of cardiac output: Reproducibility and validation. Eur Heart J. 1990;11:49–66 suppl 1
  26. Nie NH, Hull CH, Jenkins JG, et al.  Statistical Package for Social Sciences. ed 2. New York, NY: McGraw-Hill; 1975;
  27. Patsch JR, Prasad S, Gotto AM, et al.  High density lipoprotein2. In: Relationship of the plasma levels of this lipoprotein species to its composition, to the magnitude of postprandial lipemia, and to the activities of lipoprotein lipase and hepatic lipase. ed 2. J Clin Invest. 80:1987;p. 341–347
  28. Levy E, Deckelbaum RJ, Thibault RL, et al.  In vitro remodelling of plasma lipoproteins in whole plasma by lipoprotein lipase in primary and secondary hypertriglyceridaemia. Eur J Clin Invest. 1990;20:422–431
  29. Marotta T, Ferrara LA, Pasanisi F, et al.  Enhancement of exogenous triglyceride removal following calcium channel blockade. Artery. 1989;16:312–326
  30. Eckel RH. Lipoprotein lipase. In: A multifunctional enzyme relevant to common metabolic diseases. ed 2. N Engl J Med. 320:1989;p. 1060–1068
  31. Ashby P, Bennett DP, Spencer IM, et al.  Post-translational regulation of lipoprotein lipase activity in adipose tissue. Biochem J. 1978;176:865–872
  32. Farese RV, Yost TJ, Eckel RH. Tissue-specific regulation of lipoprotein lipase activity by insulin/glucose in normal-weight humans. Metabolism. 1991;40:214–216
  33. Zavaroni I, Bonora E, Pagliara M, et al.  Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med. 1989;320:702–706
  34. Zavaroni I, Dall'Aglio E, Alpi O, et al.  Evidence for an independent relationship between plasma insulin and concentration of high density lipoprotein cholesterol and triglyceride. Atherosclerosis. 1985;55:259–266
  35. Stalder M, Pometta D, Suenram A. Relationship between plasma insulin levels and high density lipoprotein cholesterol levels in healthy men. Diabetologia. 1981;21:544–548
  36. Capaldo B, Rivellese A, Santoro D, et al.  Relationship between insulin response to intravenous glucose and plasma lipoproteins in healthy men. Artery. 1985;13:108–126
  37. Laakso M. How good a marker is insulin level for insulin resistance?. Am J Epidemiol. 1993;137:959–965
  38. Frayn KN. Insulin resistance and lipid metabolism. Curr Opin Lipidol. 1993;4:197–204
  39. Miesenböck G, Patsch JR. Postprandial hyperlipidemia: The search for the atherogenic lipoprotein. Curr Opin Lipidol. 1992;3:196–201
  40. Taskinen M-R, Kuusi T, Helve E, et al.  Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes. Arteriosclerosis. 1988;8:168–177
  41. Tuck ML. Obesity, the sympathetic nervous system, and essential hypertension. Hypertension. 1992;19:I67–I77 (suppl)
  42. Mathias CJ. Role of sympathetic efferent nerves in blood pressure regulation and in hypertension. Hypertension. 1991;18:22–30 suppl 3
  43. Rowe JW, Young JB, Minaker KL, et al.  Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes. 1981;30:219–225
  44. Ferrara LA, Di Marino L, Russo O, et al.  Doxazosin and captopril in mildly hypercholesterolemic hypertensive patients. In: The Doxazosin-Captopril in Hypercholesterolemic Hypertensives Study. ed 2. Hypertension. 21:1993;p. 97–104
  45. Medical Research Council Working Party . MRC trial of treatment of mild hypertension: Principal results. Br Med J. 1985;291:97–104
  46. Mancini M, Ferrara LA, Strazzullo P, et al.  Metabolic disturbances and antihypertensive therapy. J Hypertens. 1991;9:S47–S50 suppl 3
  47. Maling TJB, Ferrara LA, Mucklow JC, et al.  Blood pressure and plasma noradrenaline during single high-dose beta adrenoceptor blockade. Eur J Clin Pharmacol. 1979;15:375–379
  48. Day JL, Metcalfe J, Simpson CN. Adrenergic mechanism in control of plasma lipid concentrations. Br Med J. 1982;284:1145–1148
  49. Murphy MB, Sugrue D, Trayner I, et al.  Effects of short term beta adrenoreceptor blockade on serum lipids and lipoproteins in patients with hypertension or coronary artery disease. Br Heart J. 1984;51:589–594

PII: 0026-0495(95)90182-5

Metabolism - Clinical and Experimental
Volume 44, Issue 6 , Pages 712-718 , June 1995

Article Tools